ELI LILLY AND COMPANY (LLY) Share buybacks
- Total buybacks · last 12 months (USD): Value $6.17B; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $6.17B | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 6.17B USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $6.17B | (m) | (m) |
| 2026-03-31 | $5.26B | (m) | (m) |
| 2025-12-31 | $4.11B | (m) | (m) |
| 2025-09-30 | $4.65B | (m) | (m) |
| 2025-06-30 | $4.39B | (m) | (m) |
| 2025-03-31 | $3.70B | (m) | (m) |
| 2024-12-31 | $2.50B | (m) | (m) |
| 2024-09-30 | $446.10M | (m) | (m) |
| 2024-06-30 | $0.00 | (m) | (m) |
| 2024-03-31 | $0.00 | (m) | (m) |
| 2023-12-31 | $750.00M | (m) | (m) |
| 2023-09-30 | $750.00M | (m) | (m) |
| 2023-06-30 | $750.00M | (m) | (m) |
| 2023-03-31 | $750.00M | (m) | (m) |
| 2022-12-31 | $1.50B | (m) | (m) |
| 2022-09-30 | $2.25B | (m) | (m) |
| 2022-06-30 | $2.25B | (m) | (m) |
| 2022-03-31 | $2.75B | (m) | (m) |
| 2021-12-31 | $1.25B | (m) | (m) |
| 2021-09-30 | $500.00M | (m) | (m) |
| 2021-06-30 | $500.00M | (m) | (m) |
| 2021-03-31 | $0.00 | (m) | (m) |
| 2020-12-31 | $500.00M | (m) | (m) |
| 2020-09-30 | $800.00M | (m) | (m) |
| 2020-06-30 | $1.40B | (m) | (m) |
| 2020-03-31 | $1.40B | (m) | (m) |
| 2019-12-31 | $4.40B | (m) | (m) |
| 2019-09-30 | $5.20B | (m) | (m) |
| 2019-06-30 | $5.60B | (m) | (m) |
| 2019-03-31 | $6.55B | (m) | (m) |
| 2018-12-31 | $4.15B | (m) | (m) |
| 2018-09-30 | $3.15B | (m) | (m) |
| 2018-06-30 | $2.15B | (m) | (m) |
| 2018-03-31 | $1.40B | (m) | (m) |
| 2017-12-31 | $299.80M | (m) | (m) |
| 2017-09-30 | $499.90M | (m) | (m) |
| 2017-06-30 | $499.90M | (m) | (m) |
| 2017-03-31 | $300.00M | (m) | (m) |
| 2016-12-31 | $600.10M | (m) | (m) |
| 2016-09-30 | $553.00M | (m) | (m) |
| 2016-06-30 | $614.10M | (m) | (m) |
| 2016-03-31 | $739.00M | (m) | (m) |
| 2015-12-31 | $749.50M | (m) | (m) |
| 2015-09-30 | $796.60M | (m) | (m) |
| 2015-06-30 | $1.04B | (m) | (m) |
| 2015-03-31 | $1.06B | (m) | (m) |
| 2014-12-31 | $800.00M | (m) | (m) |
| 2014-09-30 | $1.00B | (m) | (m) |
| 2014-06-30 | $700.00M | (m) | (m) |
| 2014-03-31 | $555.00M | (m) | (m) |
| 2013-12-31 | $1.70B | (m) | (m) |
| 2013-09-30 | $1.92B | (m) | (m) |
| 2013-06-30 | $1.92B | (m) | (m) |
| 2013-03-31 | $1.92B | (m) | (m) |
| 2012-12-31 | $721.10M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) |
| 2011-12-31 | $0.00 | (m) | (m) |
| 2010-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |